Pfizer’s Pipeline Potential and Strong Earnings Fuel Investor Optimism

Pfizer Inc. has delivered a robust quarterly performance, surpassing market forecasts and providing a stable financial foundation. However, the most compelling narrative for shareholders may lie ahead, embedded within the company's development pipeline, particularly its advances in the competitive obesity drug market.

For the fourth quarter of 2025, the pharmaceutical giant reported revenue of $17.56 billion, outperforming the consensus estimate of $16.93 billion. The company also demonstrated strength on the bottom line, with adjusted earnings per share reaching $0.66, a clear beat against the projected $0.57.

This solid quarterly report contributes to a positive trend for the equity. Since the start of the year, Pfizer shares have gained 6.86 percent, with a recent trading price of €22.59.

Strategic Focus on Future Growth

Management has reaffirmed its financial guidance for the full 2026 fiscal year. The company continues to anticipate adjusted earnings per share in the range of $2.80 to $3.00. This forecast already accounts for an estimated $1.5 billion revenue impact from the loss of market exclusivity for certain products. Pfizer also maintains its expectation of approximately $5 billion in revenue from its COVID-19 product portfolio.

Should investors sell immediately? Or is it worth buying Pfizer?

The strategic emphasis for the current business year is on advancing late-stage pipeline assets. The company plans to initiate around 20 registration-enabling studies. A key date for investors is June 6, 2026, when Pfizer is scheduled to present detailed results from a promising study on its novel obesity drug candidate.

GLP-1 Candidate Shows Promise in Competitive Arena

While current financials indicate stability, the company's research pipeline is generating significant interest. Pfizer has released positive topline data from a Phase 2b trial for its GLP-1 receptor agonist, PF-'3944. This injectable weight-loss candidate met its primary endpoint, demonstrating a statistically significant reduction in body weight after 28 weeks.

The data suggests a competitive tolerability profile, which is crucial for market positioning. Furthermore, weight loss was maintained even after transitioning patients from a weekly to a monthly dosing schedule—a potential major convenience benefit that could differentiate the treatment.

Key Financial and Pipeline Data

• Q4 2025 Revenue: $17.56 billion (above expectations)
• Adjusted Earnings Per Share: $0.66 (above expectations)
• 2026 Revenue Guidance: $59.5 to $62.5 billion
• 2026 EPS Guidance: $2.80 to $3.00
• Pipeline Highlight: Successful Phase 2b data for obesity candidate PF-'3944